A clinical study on enhanced antitumor activity of　5-fluorouracil by a methionine-free amino acid solution　as a biochemical modulator. by Maeta, Michio et al.





A c1inical study on enhanced antitumor activity of 
5-fluorouracil by a methionine-free amino acid solution 
as a biochemical modulator. 
Michio MAETA， Tetsuya KANEKO， Nobuaki KAIBARA 
Deρartment 01 s抑 -geη，FaωJちI01 Medicine， 
jrotori [Jniversiか，Yonago 683， Japan. 
ABSTRACT 
A study of the effects of methionine-free amino acid solutioh (AO-90) on the metabolism 
of 5-fluorouracil (5-FU) was performed in patients with advanced gastric or colorectal can-
cers. Total parenteral nutrition with either AO-90 (AOjF group) or conventional amino 
acid solution(CjF group) in combination with 5-FU was performed for 7days preoperatively 
under the fasting condition. The administration of AO-90 showed a decreased level of se・
rum methionine and resulted in the subsequent increased tendency in the intratumorous lev幽
els of both folate and methylene tetrahydrofolate compared to those of the CjF group. In 
the AOjF group， the inhibition rate of thymidylate synthase in the tumor was higher than 
that of the CjF group. These results indicate that AO-90 plays an important role in the 
metabolism of 5-FU and seems to contribute to the increased antitumor effect of 5-FU as 
a biochemical modulator. 
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し一口イシン 1.23 1.40 
しーイソロイシン 0.55 0.80 
L-パリン 0.61 0.80 
酢酸 Lー リジン 2.10 1.48 
(しーリジンとして) (1.49) (1.05) 
しートレオニン 0.54 0.57 
Lー トリフトファン 0.18 0.20 
Lー メチオニン 0.39 
しーフェニルアラニン 0.87 0.70 
しーシステイン 0.10 
しーチロシン 0.05 
しーアルギニン 0.66 1.05 




アミノ酢酸 1.00 0.59 
しーアスパラギン酸 0.10 
しーグルタミン酸 0.10 
総アミノ酸震 7.43 10.00 
総窒素量 1.19 1.57 
メチオニン欠如アミノ酸輸液の5-FU効果増強
(day) -7 “5 -4 開6
5-FU ~ 
157 





750 ml/day/TPN • 
* C/F群はAO-90の代わりに比較検討としてアミパレン③を手術日7~6目前の2日間を















生化学的検査， rapid turnover proteinおよびア
ミノ酸分析等を行ないAO-90投与による影響を
調査した.
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図7.組織内5-FU濃度
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測定したTS. free， TS. totalより求められたTS
阻害率を図13に示した {TS阻害率 (X)= 














































麗蕩組織 •• • 1・? 下側四分位点上保.lJg分位点
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